Edition:
United Kingdom

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

20.84USD
4:07pm GMT
Change (% chg)

$0.79 (+3.94%)
Prev Close
$20.05
Open
$20.20
Day's High
$21.27
Day's Low
$20.20
Volume
51,066
Avg. Vol
205,308
52-wk High
$53.89
52-wk Low
$19.73

Latest Key Developments (Source: Significant Developments)

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Five Prime posts Q3 loss of $1.54 per share
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Five Prime Therapeutics Inc :Five prime announces third quarter 2017 results and provides business update.Q3 loss per share $1.54.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.Five prime therapeutics inc - ‍collaboration revenue for q3 of 2017 increased by $1.6 million to $8.3 million​.  Full Article

Five Prime Therapeutics appoints Aron Knickerbocker as CEO
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Five Prime Therapeutics Inc :Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018.Five Prime Therapeutics Inc - ‍ selected Aron Knickerbocker to succeed Lewis Williams, as president and CEO​.Five Prime Therapeutics Inc - ‍ Knickerbocker will maintain chief operating officer position until end of 2017​.  Full Article

Five Prime announces Q2 2016 results and provides business update
Thursday, 4 Aug 2016 

Five Prime Therapeutics Inc : Five prime announces second quarter 2016 results and provides business update . Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S . Q2 revenue $9.2 million versus $6.3 million . Q2 loss per share $0.49 .Q2 revenue view $6.4 million -- Thomson Reuters I/B/E/S.  Full Article

Five Prime says entered amendment to license agreement with Galaxy Biotech
Friday, 20 May 2016 

Five Prime Therapeutics Inc : Entered into an amendment to exclusive license agreement with galaxy biotech, llc - sec filing . Co, galaxy revised milestone definitions, reduced certain milestone payments,added 4 development-related milestone payments .Amount of development-related milestone payments that fiveprime will be obligated to pay was decreased by $0.5 million.  Full Article

Five Prime Therapeutics receives FDA orphan drug designation for FPA008
Wednesday, 13 Jan 2016 

Five Prime Therapeutics:Says FDA has granted orphan drug designation for FPA008 for the treatment of Pigmented Villonodular Synovitis.  Full Article

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors